Overview: Agilent delivered $1.74 billion in Q3 2025 revenue, marking the fifth straight quarter of sequential core revenue acceleration with a 6.1% core growth on a two-year stack that continued to improve. Management raised full-year 2025 guidance to $6.91–$6.93 billion (core growth mid-single digits at the midpoint) on stronger end-market demand across pharma, chemicals and advanced materials, CrossLab, and diagnostics. Net income of $336 million and EPS of $1.18 highlighted a durable top-line expansion, though near-term margins faced headwinds from tariffs, currency, and capacity expansion downtime at BioVectra.
Drivers: Growth was broad-based with pharma up 9% (small molecules up in the low-to-mid teens with Infinity Tree LC adoption driving value), chemicals and advanced materials up 10% (semiconductor and GC/GCMS ramp), and CrossLab delivering mid-single-digit gains. NASD and BioVectra contributed meaningfully within the Life Sciences and Diagnostics segment, supported by ongoing CDMO demand and lab productivity initiatives. The Infinity Tree LC platform and Pro IQ LCMS are expanding app coverage, underpinning sustained revenue growth into FY 2026 and beyond. Geographic momentum remained robust outside the US, notably Asia ex China and Europe, with India emerging as a strategic growth hub.
Outlook: Q4 2025 is expected to be the strongest quarter of the year, with core revenue growth projected at ~5.4% and roughly $100 million incremental revenue at the midpoint vs. Q3. Full-year 2025 EPS is guided to $5.56–$5.59, with a tax rate of ~12%. The company anticipates margin expansion in Q4 (~230 basis points sequentially) driven by fixed-cost leverage, volume, and Ignite benefits, offset by higher tariff costs. Management remains committed to tariff mitigation into FY 2026 and views Ignite as a durable growth engine and competitive differentiator. Investors should monitor tariff progression, FX headwinds, R&D/Go-To-Market investment, and the cadence of platform launches as key drivers of 2026 profitability and growth.